Published in Front Neurosci on October 31, 2014
The Role of Oxidative Damage in the Pathogenesis and Progression of Alzheimer's Disease and Vascular Dementia. Oxid Med Cell Longev (2015) 0.81
Recent imaging advances in neurology. J Neurol (2015) 0.81
Amyloid Imaging: Poised for Integration into Medical Practice. Neurotherapeutics (2017) 0.79
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 23.30
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 7.66
Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging (2005) 5.83
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
Alzheimer's disease. Lancet (2011) 5.35
Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res (2008) 5.29
Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci (2010) 5.03
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci (2009) 4.50
2011 Alzheimer's disease facts and figures. Alzheimers Dement (2011) 3.91
National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement (2011) 3.42
Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol (2014) 3.19
Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med (2010) 2.77
19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci (2005) 2.44
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) (2010) 2.21
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci (2005) 2.17
Synaptic degeneration in Alzheimer's disease. Acta Neuropathol (2009) 1.93
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia (2012) 1.90
Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging (2006) 1.87
Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci (2007) 1.85
Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol (2010) 1.78
Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull (2003) 1.76
Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci U S A (1999) 1.73
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol (2009) 1.67
In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med (2004) 1.65
Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage (2011) 1.64
Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment. Behav Neurol (2009) 1.63
Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol (2009) 1.61
Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. Behav Neurol (2009) 1.58
Neuropathology of Alzheimer's disease. Mt Sinai J Med (2010) 1.57
Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Int Psychogeriatr (2013) 1.53
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des (2010) 1.50
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A (2005) 1.47
'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci (2010) 1.47
Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr Alzheimer Res (2006) 1.44
In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci (2005) 1.42
Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis (2002) 1.42
MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med (2004) 1.37
Discriminative analysis of early Alzheimer's disease using multi-modal imaging and multi-level characterization with multi-classifier (M3). Neuroimage (2011) 1.37
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med (2003) 1.35
Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis (2010) 1.33
Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol (2011) 1.32
Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis (2008) 1.31
Quantitative MR imaging in Alzheimer disease. Radiology (2006) 1.29
Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis (2010) 1.28
Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn Reson Med (2005) 1.27
Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from alzheimer's disease patients. Magn Reson Med (2007) 1.27
Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci (2004) 1.23
Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res (2006) 1.23
Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain (2010) 1.22
APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct Funct (2009) 1.20
Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol (2005) 1.19
In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci (2011) 1.19
Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn Reson Med (2004) 1.19
The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2006) 1.18
MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J Magn Reson Imaging (2009) 1.18
Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects. Mol Neurobiol (2010) 1.17
Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn Reson Med (2004) 1.17
Mechanisms of amyloid plaque pathogenesis. Acta Neuropathol (2007) 1.17
Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem (2006) 1.16
In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiol Aging (2005) 1.15
Hybrid FMT-CT imaging of amyloid-beta plaques in a murine Alzheimer's disease model. Neuroimage (2008) 1.14
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7T system. J Neuroimaging (2007) 1.14
In vivo measurement of plaque burden in a mouse model of Alzheimer's disease. J Magn Reson Imaging (2006) 1.13
Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Neuroscientist (2007) 1.13
Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen (2009) 1.12
Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci (2004) 1.12
Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed (2002) 1.11
PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2005) 1.11
A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int (2010) 1.10
Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med (2010) 1.09
Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol (2009) 1.09
Abeta aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med (2009) 1.09
Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J Alzheimers Dis (2011) 1.08
Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease. Neuroimage (2009) 1.07
Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. Int J Clin Exp Pathol (2010) 1.07
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. J Clin Neurol (2009) 1.06
Animal models of amyloid-beta-related pathologies in Alzheimer's disease. FEBS J (2010) 1.06
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging (2007) 1.06
Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol (2009) 1.06
Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging (2006) 1.05
Anatomical and functional phenotyping of mice models of Alzheimer's disease by MR microscopy. Ann N Y Acad Sci (2007) 1.04
Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev Mol Diagn (2010) 1.03
Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis (2005) 1.03
Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease. Neurobiol Aging (2009) 1.03
Analysis of serial magnetic resonance images of mouse brains using image registration. Neuroimage (2008) 1.02
Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res (2010) 1.00
Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis (2005) 0.99
Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res (2005) 0.99
Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice. Neurobiol Aging (2007) 0.99